ProtoKinetix Stock

ProtoKinetix ROCE

The Return on Capital Employed (ROCE) of ProtoKinetix (PKTX) as of Jul 31, 2026 is -90.91 %. In the previous year, Return on Capital Employed (ROCE) was -84.20 % — a change of 7.97% (lower).

ROCE

-90.91 %

YoY

7.97%

Last updated:

In 2026, ProtoKinetix's return on capital employed (ROCE) was -90.91 %, a 7.97% increase from the -84.20 % ROCE in the previous year.

Access this data via the Eulerpool API

ProtoKinetix Stock analysis

What does ProtoKinetix do? ProtoKinetix Inc. is a Canadian biotechnology company focused on the development of glycoproteins for therapeutic applications. The company was founded in 2005 and is headquartered in Marietta, USA. ProtoKinetix specializes in the research and development of AAGP® (Anti-Aging Glycopeptide) as biopharmaceuticals. These proprietary glycoproteins have the ability to protect cells and can be used in various therapeutic applications for improving damage in physical injury, spinal cord injury, diabetes, transplantation, and retinal diseases. In addition to the medical field, ProtoKinetix is also developing its patented technology for use in bio-agriculture and animal healthcare. It has a subsidiary that holds the rights to use and distribute AAGP® and its patents. ProtoKinetix's business model involves licensing its glycoprotein technology for various applications, including biopharmaceuticals, bioprocessing industries, and cell protection management for regenerative medicine and stem cell preparations. The company has established partnerships with other biotech companies to integrate its AAGP® technology into their product pipelines. ProtoKinetix's flagship product is the AAGP® protein solution, which is used as a medication in regenerative medicine, organ transplantation, eye healing, and animal health. It is also interested in researching the application of AAGP® in crop farming to increase yields and improve soil quality. ProtoKinetix is poised to play a significant role in the development of glycoproteins as future medicines and therapeutic technologies in various industries. It not only has the potential to explore healing medical products but also aims to enhance agriculture and animal care. ProtoKinetix represents an excellent example of a biotechnology company focused on improving the healthcare and agricultural industries. ProtoKinetix is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling ProtoKinetix's Return on Capital Employed (ROCE)

ProtoKinetix's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing ProtoKinetix's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

ProtoKinetix's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in ProtoKinetix’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about ProtoKinetix stock

Return on Capital Employed (ROCE) of ProtoKinetix is -90.91 % in 2026.

Access this data via the Eulerpool API

Profitability — ProtoKinetix

All Key Metrics — ProtoKinetix